Diabetes market was valued at $88.3 billion in 2024 and is projected to reach $354.9 billion by 2035, growing at a CAGR of 13.6% during the forecast period (2025–2035). The global diabetes market is witnessing sustained growth as awareness programs and public health initiatives improve early diagnosis and long-term disease management. Increasing screening efforts, lifestyle changes, and growing prevalence of obesity are contributing to a rising diagnosed population across both developed and emerging economies.
Browse the full report description of “Diabetes Market Size, Share & Trends Analysis Report by Type (Type 1 Diabetes, Type 2 Diabetes, and Gestational), by Drug Class (Alpha-Glucosidase Inhibitors, Amylin Analogs, Antidiabetic Combinations, Dipeptidyl Peptidase 4 Inhibitors, Incretin Mimetics, Insulin, Meglitinides, Non-Sulfonylureas, Sglt-2 Inhibitors, Sulfonylureas, and Thiazolidinedione), and by Devices (Blood Glucose Meters, Blood Glucose Strips, Insulin Injection Pens, Insulin Syringes, Continuous Glucose Monitoring Systems, Insulin Pumps, and Lancets), Forecast Period (2025-2035)” of https://www.omrglobal.com/industry-reports/diabetes-market
Advancements in diagnostic tools, continuous glucose monitoring (CGM), and digital health platforms are transforming diabetes care. These innovations support personalized treatment plans, better glycemic control, and improved patient adherence, reinforcing market expansion across therapeutics, devices, and care services.
Key Developments Highlight Momentum in the Global Diabetes Market
- 2024: Global health agencies reported increased diabetes screening and early diagnosis rates, particularly in middle-income countries, boosting demand for diagnostic and treatment solutions.
- 2024: Adoption of continuous glucose monitoring and connected insulin delivery systems accelerated as patients and providers prioritized real-time data and proactive disease management.
- 2025: Governments and healthcare organizations expanded diabetes awareness and prevention programs, supporting broader access to care and sustained growth of the global diabetes market.
Integrated Care Models and Technology-Enabled Management
Industry players are focusing on integrated diabetes management solutions that combine medications, monitoring devices, and digital coaching platforms. Strategic collaborations, patient-centric product development, and expansion into underserved regions are strengthening market presence and improving outcomes.
Recent Strategic Developments in the Global Diabetes Market
- In 2025, Medtronic plc launched its latest continuous glucose monitoring (CGM) system with enhanced accuracy and smartphone integration, designed to provide real-time glucose data and improve glycemic management for people with diabetes.
- In 2024, Dexcom, Inc. completed the acquisition of a digital therapeutics provider focused on personalized diabetes coaching and analytics, enhancing its portfolio of connected care solutions for diabetes self-management.
- In 2025, Abbott Laboratories announced a strategic partnership with a major Asian healthcare group to co?develop and deploy its FreeStyle Libre flash glucose monitoring systems across hospitals and primary care networks, aiming to expand early detection and monitoring services.
Market Coverage
- The market number available for – 2025-2035
- Base year- 2025
- Forecast period- 2026-2035
- Segment Covered-
- Competitive Landscape – Abbott Laboratories, Dexcom Inc., Eli Lilly and Co., Medtronic MiniMed Inc. and Novo Nordisk A/S.
Key questions addressed by the report.
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- Who is the leader in the market?
- How are players addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Diabetes Market Report Segment
By Type
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational
By Drug Class
- Alpha-Glucosidase Inhibitors
- Amylin Analogs
- Antidiabetic Combinations
- Dipeptidyl Peptidase 4 Inhibitors
- Incretin Mimetics
- Insulin
- Meglitinides
- Non-Sulfonylureas
- Sglt-2 Inhibitors
- Sulfonylureas
- Thiazolidinedione
By Devices
- Blood Glucose Meters
- Blood Glucose Strips
- Insulin Injection Pens
- Insulin Syringes
- Continuous Glucose Monitoring Systems
- Insulin Pumps
- Lancets
Global Diabetes Market Report Segment by Region
North America
Europe
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
Asia-Pacific
- China
- India
- Japan
- South Korea
- Australia and New Zealand
- ASEAN Economies
- Rest of Asia-Pacific
Rest of the World
- Latin America
- Middle East & Africa
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/diabetes-market